Puma Biotechnology share price today

Puma Biotechnology, Inc.'s share price was $10.69 at the close on 4 November 2026. That is 34.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $11, and at that close it sat 95% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 17 weeks in a row.

Over the last 1 year the share price moved +215% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Puma Biotechnology, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Puma Biotechnology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Puma Biotechnology, Inc. earned $8.2 M of net profit in the Jun 2026 quarter, +39.9% on the same quarter a year earlier. Full-year FY25 profit was $31.1 M. That is 14.5% of the quarter's revenue. The same quarter a year earlier earned $5.9 M. 3 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $31.1 M (+2.8% on the year before).

Why profit moved: revenue changed +7.8% on a year earlier and the margin moved +0.7 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −68.3% and revenue +0.1%. Profit is growing slower than sales: rising costs are taking part of the growth.

Puma Biotechnology, Inc. reported $56.5 M of revenue in the Jun 2026 quarter, +7.8% on the same quarter a year earlier. Over 4 years it has grown −2.5% a year on average. The last full year, FY25, came in at $228 M. The last four reported quarters add to $231 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $228 M, −0.9% on the year before.

Recent pace: the last four quarters grew +0.1% on average, against −2.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −2.9%, against +2.7% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −44.9%, against +75.0% a year (rolling over).

Puma Biotechnology, Inc.'s operating margin was 13.4% in the Jun 2026 quarter, 0.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 0.5% and 16.3%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 0.5% and 16.3%, and FY25's 16.3% is the highest of them.

Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +1.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 130% of Puma Biotechnology, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $41.8 M of operating cash against $31.1 M of profit. After $71.0 K of spending on assets, $41.7 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Puma Biotechnology, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $267 K on assets over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $267 K over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Puma Biotechnology, Inc.'s P/E is 21.2×, about the highest it has ever been. Its usual P/E (the middle reading) is 11.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −1.6% while the price moved +78.5%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Puma Biotechnology, Inc.'s business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +282.8% at its peak to −44.9% now), while ROCE is still 23.5%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: slowing from a peak is where good stories often end quietly.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Puma Biotechnology, Inc. earned a ROE of 24% in FY25. That is up from a low of 0% in FY22. Its return on capital used (ROIC) is 44.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.6% net margin and 1.06× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 13.6% net margin × 1.06× asset turnover × 1.66× leverage (assets divided by equity) ≈ 23.9% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 56.5% − 12.0% = +44.5 percentage points. The 12.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 56.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 51.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Puma Biotechnology, Inc. has total debt of $4.8 M against shareholder equity of $139 M as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from −47.69 in FY21 to 0.22 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

11.3% of Puma Biotechnology, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 13.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Puma Biotechnology, Inc., the Z-score is −3.73. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of −3.73 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Puma Biotechnology, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Puma Biotechnology is the 137th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Crescent Biopharma, Inc., Aclaris Therapeutics, Inc. and Surrozen, Inc. Just below it: Valneva SE, Ovid Therapeutics Inc. and Capricor Therapeutics, Inc.

Biotechnology companies close in size

134. Crescent Biopharma, Inc. $592 million
135. Aclaris Therapeutics, Inc. $570 million
136. Surrozen, Inc. $554 million
137. Puma Biotechnology, Inc. $552 million
138. Valneva SE $539 million
139. Ovid Therapeutics Inc. $535 million
140. Capricor Therapeutics, Inc. $519 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2820. Ponce Financial Group, Inc. $529 million · Banks - Regional
2821. Boost Run, Inc. $528 million · Software - Infrastructure
2822. Puma Biotechnology, Inc. $528 million
2823. Surrozen, Inc. $527 million · Biotechnology
2824. Valneva SE $526 million · Biotechnology

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.